Results 141 to 150 of about 5,286 (232)
Mutations Of Bruton's Tyrosine Kinase Gene In Brazilian Patients With X-linked Agammaglobulinemia.
, 2015 Mutations in Bruton's tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood.
Roxo Júnior, P +4 more
core
Image_3_Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.JPEG
, 2018 Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia (5724011) +5 more
core +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Background Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T‐cell (CAR‐T) therapy.
Enver Aydilek +6 more
wiley +1 more source
Image_2_Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.JPEG
, 2018 Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia (5724011) +5 more
core +1 more source
BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad +5 more
wiley +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview
MedComm, Volume 7, Issue 6, June 2026.The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele +7 more
wiley +1 more source
Use of biomolecular emulator for characterizing flexible proteins by small‐angle x‐ray scattering
Protein Science, Volume 35, Issue 6, June 2026.Abstract Flexible proteins populate heterogeneous conformational ensembles that are essential for their function. Small‐angle x‐ray scattering (SAXS) is widely used to study protein structure in solution and to characterize conformational heterogeneity.
Yoni Haitin, Bar Manori, Moshe Giladi
wiley +1 more source
Breaking Barriers Between Species: Integrated Multi‐Species PK Models Improve Human PK Predictions
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.ABSTRACT The accurate prediction of human pharmacokinetics (PK) is critical for compound selection and determining the human efficacious dose in drug discovery. Besides predicting the key PK parameters clearance (CL) and steady‐state distribution volume (Vss), the prediction of exposure metrics, e.g., maximum and trough concentrations (Cmax, Ctrough ...
Miriam S. R. Happ +6 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin +27 more
wiley +1 more source